{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:O43593",
      "entity_text" : "HR",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "uniprot:Q96KF2",
      "entity_text" : "PRAC",
      "entity_type" : "protein"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "Ivabradine benefit-risk ratio was reassessed by the Pharmacovigilance Risk Assessment Committee (PRAC) in November 2014 and was found to remain positive for its authorized indications.4 The PRAC recommended to increase the resting HR threshold of patients with angina pectoris from greater than 60 to greater than or equal to 70 bpm before treatment initiation, contraindicate concomitant use of ivabradine with verapamil or diltiazem, and reinforce current posology including initial (5-mg bid) and maintenance (7.5-mg bid) maximal doses.",
  "reading_complete" : "2020-08-05T22:03:50Z",
  "reader_type" : "machine",
  "reading_started" : "2020-08-05T22:02:33Z",
  "trigger" : "increase",
  "evidence" : [ "PRAC recommended to increase the resting HR" ],
  "pmc_id" : "6899761",
  "score" : 0
}